The FDA this week announced revised draft guidance that it says will help ensure that citizen petitions cannot be used by brand-name drug makers to delay the market entry of generics or biosimilars of branded products.
The FDA this week announced revised draft guidance that it says will help ensure that citizen petitions cannot be used by brand-name drug makers to delay the market entry of generics or biosimilars of branded products.
Citizen petitions allow any interested party to ask the FDA Commissioner to amend agency regulations or to take (or refrain from taking) an administrative action. The FDA is required to respond to such petitions within 150 days of filing.
While the Food and Drug Administration Safety and Innovation Act, enacted in 2012, holds that approval of a pending drug application must not be delayed because of a request for action unless the written request convinces the FDA that a delay is necessary to protect the public health, citizen petitions have been the subject of controversy. During the FDA’s 2017 meeting on administering the Hatch-Waxman amendments, numerous stakeholders raised the question of whether citizen petitions filed by brand-name drug makers could be used to forestall competition.
Learn more about citizen petitions.
In a statement announcing the new guidance, FDA Commissioner Scott Gottlieb, MD, noted that, “While the record shows that citizen petitions have rarely delayed specific generic drug approvals, there’s no doubt that the process requirements associated with [citizen petitions] can add to resource burdens on the generic drug review process and the FDA’s regulatory decision making.”
The new guidance, Gottlieb explained, will help to improve the agency’s review process efficiency as a way to discourage companies from improperly filing petitions.
A key feature of the guidance is FDA’s stated intention to refer to the Federal Trade Commission (FTC) any petitions that have been submitted with an apparent intention to thwart competition. That announcement comes after the FDA signaled its intention to work more closely with the FTC earlier this year.
The guidance indicates that the FDA may determine that a petition was submitted with the primary purpose of delaying an application’s approval based on a number of criteria, including, among others:
In addition to sending such petitions to the FTC for further scrutiny, says the FDA, the agency will highlight such petitions in its annual report to Congress.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.